The BCR-ABL Breakpoint Detection by RT PCR test identifies the specific genetic fusion responsible for chronic myeloid leukemia (CML) and some acute leukemias. Metropolis Healthcare performs this highly sensitive molecular test to detect and characterize the BCR-ABL transcript from an EDTA blood sample. Accurate breakpoint detection supports diagnosis, prognosis, and monitoring of treatment response. This test is essential for guiding targeted therapy and ensuring effective long-term disease management in affected patients.
Price:
Rs. 4,770.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes: B0083
Frequently Asked Questions (FAQ's):
What does the BCR-ABL Breakpoint Detection test include at Metropolis Healthcare?
It detects and characterizes the BCR-ABL fusion transcript associated with specific leukemias.
How does Metropolis Healthcare perform this RT PCR test?
Metropolis Healthcare uses highly sensitive reverse transcriptase PCR to identify and quantify the breakpoint.
Who should take the BCR-ABL / EDTA Blood test at Metropolis Healthcare?
Patients suspected of having CML or those already diagnosed and undergoing treatment monitoring may require this test.
Do I need any preparation before giving my blood sample at Metropolis Healthcare?
No special preparation is required unless your clinician advises otherwise.
How soon can I get results from Metropolis Healthcare?
Results are usually available within the turnaround time for molecular oncology testing.
Is the test reliable at Metropolis Healthcare?
Yes, Metropolis Healthcare follows strict molecular quality standards to ensure precise results.
How can this test help my doctor at Metropolis Healthcare?
It helps confirm diagnosis, choose targeted therapy, and monitor treatment effectiveness.
Do I need a prescription for this test at Metropolis Healthcare?
A prescription is recommended to ensure correct interpretation and clinical follow-up.